



09-04-02

RECEIVED
7636
SEP 06 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Micheal L. Gruenberg
Serial No.: 10/071,016
Filed: February 7, 2002
For: **Th1-CELL ADOPTIVE
IMMUNOTHERAPY**
Art Unit: 1636
Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS

MAIL"

"Express Mail" Mailing Label Number

EV177690260

Date of Deposit August 29, 2002

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to:

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Alicia Bradbury

Date

Alicia Bradbury 8/29/02

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Information Disclosure Statement and Forms PTO-1449 (28 pages) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

(X) The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

* * *

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE

By:

Stephanie L. Seidman
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket 24731-504B
Address all correspondence to:
HELLER EHRMAN WHITE & McAULIFFE
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com



RECEIVED

SEP 06 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Micheal L. Gruenberg
Serial No.: 10/071,016
Filed: February 7, 2002
For: **Th1-CELL ADOPTIVE
IMMUNOTHERAPY**
Art Unit: 1636
Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS
MAIL"

"Express Mail" Mailing Label Number

EV177690260

Date of Deposit August 29, 2002 #4

I hereby certify that this paper is being deposited
with the United States Postal "Express Mail Post
Office to Addressee" Service under 37 C.F.R.
§1.10 on the date indicated above and addressed
to:

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Alicia Bradbury
Alicia Bradbury

8/29/02
Date

**INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97-1.98**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Because this Information Disclosure Statement is filed before receipt of a First Office Action on the merits for the above-captioned application, no fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (28 pages) are provided herewith in connection with the above-captioned application. In accordance with 37 C.F.R. §1.98(d), copies of the references listed on the Form PTO-1449 which have been previously provided in connection with applications U.S. Serial No. 09/957,194

U.S.S.N. 10/071,016
GRUENBERG
Information Disclosur Statement

which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120, are not provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language except for items CL, JG, KK, and NC. Item CL (Japanese Patent No. JP 2883201) is in the Japanese language and is supplied with a certified English language translation (item EA), an English language Derwent abstract describing the subject matter (item FC), and a corresponding International Publication WO 90/05541 (item CM). Item JG (Mantovani et al.) is in the Spanish language and contains an English language abstract. Items KK and NC (Okutoni *et al.* and Tanaka *et al.*, respectively) are in the Japanese language and contain an English language abstract. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common.

<u>U.S.S.N.(App. no.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
08/700,565	07/25/96	500B
09/127,411	07/31/98	500C
09/127,142	07/31/98	500D
09/127,138	07/31/98	500E
09/127,141	07/31/98	500F
09/824,906	04/02/01	500G
10/155,404	05/22/02	500H
09/957,194	09/11/01	504
10/094,667	03/07/02	508

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the

U.S.S.N. 10/071,016
GRUENBERG
Information Discl sur Statement

filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing reference and it be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By: _____

Stephanie Seidman
Registration No. 33,779

Attorney Docket 24731-504B
Address all correspondence to:
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com



AUG 20 2002

FORM PTO 1449 (Modified)

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

RECEIVED

SEP 06 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	0	1	9	0	4	8	02/14/02	Berenson	435	372	05/24/01
	B	0	0	3	1	2	5	3	10/18/01	Gruenberg	424	93.1	04/02/01
	C	0	0	5	3	3	6	1	12/20/01	Thompson <i>et al.</i>	424	143.1	06/07/95
	D	3	8	2	1	0	8	7	6/28/74	Knazek <i>et al.</i>	195	127	5/18/72
	E	3	8	8	3	3	9	3	5/13/75	Knazek <i>et al.</i>	195	1.8	2/11/74
	F	3	9	9	7	3	9	6	12/14/76	Delente	195	1.8	7/02/73
	G	4	0	8	7	3	2	7	5/02/78	Feder <i>et al.</i>	195	1.7	4/12/76
	H	4	2	0	0	6	8	9	4/29/80	Knazek <i>et al.</i>	435	2	8/29/78
	I	4	2	0	6	0	1	5	6/03/80	Knazek <i>et al.</i>	435	2	8/29/78
	J	4	2	2	0	7	2	5	09/02/80	Knazek <i>et al.</i>	435	285	4/03/78
	K	4	3	0	1	2	4	9	11/17/81	Markus <i>et al.</i>	435	235	7/23/80
	L	4	3	9	1	9	1	2	7/5/83	Yoshida <i>et al.</i>	435	241	9/18/80
	M	4	5	4	6	0	8	3	10/08/85	Meyers <i>et al.</i>	435	240	4/22/83
	N	4	6	2	9	6	8	6	12/16/86	Gruenberg	435	1	06/14/82
	O	4	6	9	0	9	1	5	09/01/87	Rosenberg	514	2	08/08/85
	P	4	7	2	2	9	0	2	02/02/88	Harm <i>et al.</i>	435	284	11/04/85
	Q	4	8	0	4	6	2	8	02/14/89	Cracauer <i>et al.</i>	435	240.242	08/19/87
	R	4	8	0	8	1	5	1	02/28/89	Dunn, Jr. <i>et al.</i>	604	6	04/27/87
	S	4	8	4	9	3	2	9	07/18/89	Leung <i>et al.</i>	435	2	04/20/87
	T	4	8	6	1	5	8	9	08/29/89	Ju	424	93	03/23/87
	U	4	8	9	4	3	4	2	01/16/90	Guinn <i>et al.</i>	435	291	09/22/86
	V	4	9	3	7	0	7	1	06/26/90	Cioco <i>et al.</i>	424	85.2	12/29/87
	W	4	9	7	1	7	9	5	11/20/90	Longenecker <i>et al.</i>	424	93	07/21/88
	X	4	9	7	3	5	5	8	11/27/90	Wilson <i>et al.</i>	435	240.242	04/28/88

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	Y	4	9	9	9	2	9	8	03/12/91	Wolfe <i>et al.</i>	435	240.242	04/27/88
	Z	5	0	0	2	8	7	9	03/26/91	Bowlin <i>et al.</i>	435	71.1	12/05/89
	AA	5	0	1	5	5	8	5	05/14/91	Robinson	435	240.242	02/23/88
	AB	5	0	4	1	2	8	9	08/20/91	Phillips <i>et al.</i>	424	85.2	11/13/87
	AC	5	0	5	7	4	2	3	10/15/91	Hiserodt <i>et al.</i>	435	240.23	12/18/87
	AD	5	0	6	1	6	2	0	10/29/91	Tsukamoto <i>et al.</i>	435	7.21	03/30/90
	AE	5	0	6	4	7	6	4	11/12/91	Besnainon <i>et al.</i>	435	285	12/19/89
	AF	5	0	8	1	0	2	9	01/14/92	Zarling <i>et al.</i>	435	172.3	02/01/89
	AG	5	1	2	3	9	0	1	06/23/92	Carew	604	5	
	AH	5	1	2	6	1	3	2	06/30/92	Rosenberg	424	93	08/21/89
	AI	5	1	2	6	2	3	8	06/30/92	Gebhard <i>et al.</i>	435	3	02/15/90
	AJ	5	1	4	7	2	8	9	09/15/92	Edelson	604	4	03/29/90
	AK	5	1	4	7	7	8	4	09/15/92	Peault	435	7.24	04/12/90
	AL	5	1	6	2	2	2	5	11/10/92	Sager <i>et al.</i>	435	240.243	07/15/91
	AM	5	1	9	2	5	3	7	03/09/93	Osband	424	85.2	08/19/91
	AN	5	2	0	2	2	5	4	04/13/93	Amiot <i>et al.</i>	435	240.242	10/11/90
	AO	5	2	2	9	1	1	5	07/20/93	Lynch	424	93	07/26/90
	AP	5	2	4	2	6	8	7	09/07/93	Tykocinski <i>et al.</i>	424	93	04/25/91
	AQ	5	2	7	7	9	0	7	01/11/94	Loria	424	93	07/24/92
	AR	5	3	1	6	7	6	3	05/31/94	Ochoa <i>et al.</i>	424	85.2	07/10/92
	AS	5	3	2	6	7	6	3	07/05/94	Gluchowski <i>et al.</i>	514	249	01/29/93
	AT	5	3	7	4	5	4	9	12/20/94	Leung	435	240.2	01/31/91
	AU	5	3	9	9	3	4	6	03/21/95	Anderson <i>et al.</i>	424	93.21	03/30/94
	AV	5	3	9	9	3	4	7	03/21/95	Trentham <i>et al.</i>	424	184.1	09/25/92

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AW	5	4	0	9	8	1	3	04/24/95	Schwartz	435	7.24	09/30/93
	AX	5	4	1	1	7	4	9	05/02/95	Mayo <i>et al.</i>	424	578	12/23/92
	AY	5	4	3	7	9	9	4	08/01/95	Emerson <i>et al.</i>	435	240.2	12/10/93
	AZ	5	4	4	3	9	8	3	08/22/95	Ochoa <i>et al.</i>	435	240.2	03/21/88
	BA	5	4	5	9	0	6	9	10/17/95	Palsson <i>et al.</i>	435	289.1	01/06/94
	BB	5	4	6	6	5	7	2	11/14/95	Sasaki <i>et al.</i>	435	2	04/25/94
	BC	5	4	7	0	7	3	0	11/28/95	Greenberg <i>et al.</i>	435	172.3	08/08/94
	BD	5	4	7	6	9	9	7	12/19/95	Kaneshima <i>et al.</i>	800	2	05/17/94
	BE	5	4	9	8	5	3	7	03/12/96	Bresler <i>et al.</i>	435	235.1	03/09/94
	BF	5	5	1	2	4	4	4	04/30/96	Patard <i>et al.</i>	435	6	11/30/94
	BG	5	5	9	9	7	0	5	02/04/97	Cameron	435	378	11/16/93
	BH	5	6	0	5	8	2	2	02/25/97	Emerson <i>et al.</i>	435	172.3	12/01/94
	BI	5	6	2	2	8	5	7	04/22/97	Goffe	435	378	08/08/95
	BJ	5	6	2	7	0	7	0	05/06/97	Gruenberg	435	786.5	07/26/95
	BK	5	6	3	5	3	8	6	06/03/97	Palsson <i>et al.</i>	435	372	11/02/94
	BL	5	6	3	5	3	8	7	06/03/97	Fei <i>et al.</i>	435	378	04/03/95
	BM	5	6	3	7	4	8	1	06/10/97	Ledbetter <i>et al.</i>	435	69.6	09/13/93
	BN	5	6	4	6	0	4	3	07/08/97	Emerson <i>et al.</i>	435	373	03/10/95
	BO	5	6	5	6	4	2	1	08/12/97	Gebhard <i>et al.</i>	435	3	02/12/91
	BP	5	6	7	6	8	4	9	10/14/97	Sammons <i>et al.</i>	210	806	03/08/95
	BQ	5	7	1	8	8	8	3	02/17/98	Harlan <i>et al.</i>	424	9.2	02/17/94
	BR	5	7	2	8	5	8	1	03/17/98	Schwartz <i>et al.</i>	435	385	06/07/95
	BS	5	7	6	3	2	6	1	06/09/98	Gruenberg	435	286.5	12/05/96
	BT	5	7	6	3	2	6	6	06/09/98	Palsson <i>et al.</i>	435	289.1	11/07/94

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

SEP 06 2002

TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	BU	5	7	6	6	9	2	0	06/16/98	Babbitt <i>et al.</i>	435	240.1	06/06/95
	BV	5	8	1	1	3	0	1	09/22/98	Cameron	435	372	08/07/96
	BW	5	8	1	4	2	9	5	09/29/98	Martin, Jr. <i>et al.</i>	424	1.29	07/13/94
	BX	5	8	4	6	8	2	7	12/08/98	Celis <i>et al.</i>	435	384	06/06/95
	BY	5	8	5	8	3	5	8	01/12/99	June <i>et al.</i>	424	130.1	06/03/94
	BZ	5	8	7	2	2	2	2	02/16/99	Chang	530	391.1	12/18/92
	CA	5	9	9	4	1	2	6	11/30/99	Steinman <i>et al.</i>	435	325	06/17/94
	CB	6	0	4	0	1	8	0	03/21/00	Johe	435	377	05/07/97
	CC	6	1	2	9	9	1	6	10/10/00	Chang	424	179.1	11/25/92
	CD	6	1	9	4	2	0	7	02/27/01	Bell <i>et al.</i>	435	377	01/30/98
	CE	6	2	0	4	0	5	8	03/20/01	Bolton	435	448	12/16/99
	CF	6	2	5	1	3	8	5	06/26/01	Terman	424	93.7	07/22/97
	CG	6	2	5	5	0	7	3	07/03/01	Cai <i>et al.</i>	435	69.1	03/16/98
	CH	6	3	5	2	6	9	4	03/05/02	June <i>et al.</i>	424	93.71	03/10/95

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
	CI	0	4	0	5	9	7	2	1/2/91	EP A1				
	CJ	0	4	4	0	3	7	3	08/07/91	EP A1				
	CK	0	4	4	0	3	7	3	08/07/91	EP B1				
	CL	2	8	8	3	2	0	1	04/19/99	JP B2			X	
	CM	9	0	0	5	5	4	1	05/31/90	PCT				
	CN	9	0	1	5	8	7	7	12/27/90	PCT				
	CO	9	1	0	4	3	1	7	04/04/91	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
	CP	9	1	1	8	9	7	2	12/12/91	PCT				
	CQ	9	2	0	0	0	9	2	01/09/92	PCT				
	CR	9	3	1	9	7	6	7	10/14/93	PCT				
	CS	9	4	1	2	1	9	6	06/09/94	PCT				
	CT	9	4	2	2	4	8	9	10/13/94	PCT				
	CU	9	4	2	3	7	6	0	10/27/94	PCT				
	CV	9	4	2	8	9	1	2	12/22/94	PCT				
	CW	9	4	2	9	4	3	6	12/22/94	PCT				
	CX	9	5	2	9	6	7	3	11/09/95	PCT				
	CY	9	5	3	3	8	2	3	12/14/95	PCT				
	CZ	9	6	3	4	9	5	6	11/07/96	PCT				
	DA	9	6	3	4	9	7	0	11/7/96	PCT				
	DB	9	6	4	0	8	6	0	12/19/96	PCT				
	DC	9	6	4	0	8	7	6	12/19/96	PCT				
	DD	9	7	0	5	2	3	9	2/13/97	PCT				
	DE	9	7	3	1	6	4	7	09/04/97	PCT				
	DF	9	8	2	5	4	5	7	06/18/98	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DG	Al-Saleh <i>et al.</i> , "Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix," <i>Journal of Pathology</i> <u>184</u> : 283-290 (1998)
DH	Alberts, B. <i>et al.</i> (Eds.), <i>Molecular Biology of the Cell</i> , 3rd ed., New York: Garland Publishing, Inc., pp. 1169 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

SEP 06 2002

TECH CENTER 1600/2900

RECEIVED

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DI	Anderson <i>et al.</i> , "Cross-Linking of T3 (CD3) with T4 (CD4) enhances The proliferation of resting T lymphocytes," <i>The Journal of Immunology</i> <u>139</u> : 678-682 (1987).
DJ	Anderson <i>et al.</i> , "Crosslinking CD3 with CD2 using Sepharose-immobilized antibodies enhances T lymphocyte proliferation," <i>Cell Immunology</i> <u>115</u> : 246-256 (1988).
DK	Ashkenazi <i>et al.</i> , "A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: Increased level of soluble IL-2R and reduced protein tyrosine phosphorylation," <i>Neuroimmunomodulation</i> <u>4</u> : 49-56(1997)
DL	Asselin-Paturel <i>et al.</i> , "Quantitative analysis of Th1, Th2 and TGF- β 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients," <i>Journal of Cancer</i> <u>77</u> : 7-12 (1998)
DM	Autran <i>et al.</i> , "A Th0/Th2-like function of CD4 ⁺ CD7 ⁻ T helper cells from normal donors and HIV-infected patients," <i>J. Immunol.</i> <u>154</u> : 1408-1417 (1985)
DN	Banu <i>et al.</i> , "TGF- β 1 down-regulates induced expression of both class II MHC and B7-1 on primary renal tubular epithelial cells," <i>Kidney International</i> <u>56</u> : 985-994 (1999)
DO	Baroja <i>et al.</i> "The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) provides a Helper Signal and Bypasses the Need for Accessory Cells in T-Cell Activation with Immobilized Anti-CD3 and Mitogens," <i>Cellular Immunology</i> <u>120</u> : 205-217 (1989).
DP	Baroja <i>et al.</i> "Cooperation Between an Anti-T Cell (Anti-CD28) Monoclonal Antibody and Monocyte-Produced IL-6 in the Induction of T Cell Responsiveness to IL-2," <i>The Journal of Immunology</i> <u>141</u> : 1502-1507 (1988).
DQ	Bartholeyns <i>et al.</i> , "Immune control of neoplasia by adoptive transfer of macrophages: Potentiality for antigen presentation and gene transfer," <i>Anticancer Research</i> <u>14</u> : 2673-2676 (1994)
DR	Bellone <i>et al.</i> , "Tumor-associated transforming growth factor- β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients," <i>American Journal of Pathology</i> <u>155</u> (2): 537-547(1999)
DS	Benvenuto <i>et al.</i> , "Enhanced production of interferon- γ by T lymphocytes cloned from rejected kidney grafts," <i>Transplantation</i> <u>51</u> : 887-890 (1991)
DT	Benvenuto <i>et al.</i> , "Tumor necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis," <i>Clin. Exp. Immunol.</i> <u>84</u> : 97-102 (1991)
DU	Berghella <i>et al.</i> , "The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from Th1 to Th2 and back," <i>Cancer Immunology, Immunotherapy</i> <u>45</u> : 241-249 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DV	Bernhard <i>et al.</i> , "Generation of immunostimulatory dendritic cells from human CD34 + hematopoietic progenitor cells of the bone marrow and peripheral blood," <i>Cancer Res.</i> <u>55</u> : 1099-1104 (1995)
DW	Boiardi <i>et al.</i> , "Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients," <i>Cancer Immunol. Immunother.</i> <u>39</u> : 193-197 (1994)
DX	Borst <i>et al.</i> , "The δ - and ϵ - chains of the human T3/T-cell receptor complex are distinct polypeptides," <i>Nature</i> <u>312</u> : 455-458 (1986).
DY	Brod <i>et al.</i> , "Restricted T cell expression of IL-2/Ifn- γ mRNA in human inflammatory disease," <i>J. Immunol.</i> <u>147</u> : 810-815 (1991)
DZ	Broder and Walmann, "Medical Progress: The suppressor-cell network in cancer (Second of two parts)," <i>Journal of Medicine</i> <u>299</u> (24): 1335-1341 (1978)
EA	Certified English language translation of the Japanese Patent No. 2883201.
EB	Cesano <i>et al.</i> , "Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach," <i>J. Clin. Invest.</i> <u>94</u> : 1076-1084 (1994)
EC	Ceuppens and Baroja, "Monoclonal Antibodies to the CD5 Antigen Can Provide the Necessary Second Signal for Activation of Isolated Resting T Cells by Solid-Phase-Bound OKT3," <i>The Journal of Immunology</i> <u>137</u> : 1816-1821 (1986).
ED	Chang <i>et al.</i> , "Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2," <i>Journal of Clinical Oncology</i> <u>15</u> (2): 796-807 (1997)
EE	Chen <i>et al.</i> , "Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma," <i>International Journal of Cancer</i> <u>56</u> : 755-760 (1994)
EF	Chen <i>et al.</i> , "Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and cytolytic activity of lymphocytes from malignant effusions of lung cancer patients," <i>Chest</i> <u>112</u> : 960-966 (1997)
EG	Chen <i>et al.</i> , "Donor T cells can be induced to grow and survive long term <i>in vivo</i> without previous host immunosuppression," <i>J. Immunol.</i> <u>152</u> : 4767-4774 (1994)
EH	Chen <i>et al.</i> , "Regulatory T cell clone induced by oral tolerance: Suppression of autoimmune encephalomyelitis," <i>Science</i> <u>265</u> : 1237-1240 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


EI	Cher <i>et al.</i> , "Two types of murine helper T cell clone," <i>Journal of Immunology</i> <u>138(11)</u> : 3688-3694 (1987)
EJ	Cherwinski <i>et al.</i> , "Two types of mouse helper T cell clone," <i>J. Exp. Med.</i> <u>166</u> : 1229-1244 (1987)
EK	Chick <i>et al.</i> , "Beta cell culture on synthetic capillaries: An artificial endocrine pancreas," <i>Science</i> <u>187</u> : 847-849 (1975)
EL	Clerici <i>et al.</i> , "Multiple defects of T helper cell function in newly dianosed patients with Hodgkin's Disease," <i>European Journal of Cancer</i> <u>30A(10)</u> : 1464-1470 (1994)
EM	Clerici <i>et al.</i> , "A T _H 1-T _H 2 switch is a critical step in the etiology of HIV infection," <i>Immunology Today</i> <u>14(3)</u> : 107-111 (1993)
EN	Cohen <i>et al.</i> , "CD4 ⁺ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection," <i>Critical Reviews in Immunology</i> <u>20</u> : 17-56 (2000)
EO	D'Orazio <i>et al.</i> , "A novel role for TGF- β and IL-10 in the induction of immune privilege," <i>Journal of Immunology</i> <u>160</u> : 2089-2098 (1998)
EP	Damle <i>et al.</i> , "Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin's disease," <i>Cancer Immunology, Immunotherapy</i> <u>34</u> : 205-210 (1991)
EQ	Damle <i>et al.</i> , "Differential Costimulatory Effects of Adhesion Molecules B7, ICAM-1, LFA-3, and VCAM-1 On Resting and Antigen-Primed CD4 ⁺ T Lymphocytes," <i>The Journal of Immunology</i> <u>148</u> : 1985-1992 (1992).
ER	Damle <i>et al.</i> , "Stimulation Via the CD3 and CD28 Molecules Induces responsiveness To IL-4 in CD4 ⁺ CD29 ⁺ CD45R ⁻ Memory T Lymphocytes," <i>The Journal of Immunology</i> <u>143</u> : 1761-1767 (1989)
ES	David <i>et al.</i> , "Continuous production of carcinoembryonic antigen in hollow giber cell culture units: Brief communication," <i>J. Natl. Cancer Inst.</i> <u>60(2)</u> : 303-306 (1978)
ET	Davis, J.E. <i>et al.</i> , "Mass Transfer Between Capillary Blood and Tissues", <i>Chem. Eng. J.</i> <u>7</u> : 213-225 (1974)
EU	de Waal Malefyt <i>et al.</i> , "Direct effects of IL-10 on subsets of human CD4 ⁺ T cell clones and resting T cells," <i>Journal of Immunology</i> <u>150(11)</u> : 4754-4765 (1993)
EV	de Carli <i>et al.</i> , "Cytolytic T cells with Th1- like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy," <i>J. Clinical Endocrinol. Metabol.</i> <u>77(5)</u> : 1120-1124 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EW	De Jong <i>et al.</i> , "Maturation- and differentiation-dependent responsiveness of human CD4 ⁺ T helper subsets," <i>J. Immunol.</i> <u>149</u> : 2795-2802 (1992)
EX	De Toter <i>et al.</i> , "IL4 production and increased CD30 expression by a unique CD8 T-cell subset in B-cell chronic lymphocytic leukaemia," <i>British Journal of Haematology</i> <u>104</u> : 589-599 (1999)
EY	De Vita <i>et al.</i> , "Serum interleukin-10 is an independent prognostic factor in advanced solid tumors," <i>Oncology Reports</i> <u>7</u> : 357-361 (2000)
EZ	Del Prete <i>et al.</i> , "Purified Protein derivative of <i>Mycobacterium tuberculosis</i> and excretory-secretory antigen(s) of <i>Toxocara canis</i> expand <i>in vitro</i> human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production," <i>J. Clin. Invest.</i> <u>88</u> : 346-350 (1991)
FA	Del Prete <i>et al.</i> , "High potential to tumor necrosis factor α (TNF- α) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: A peculiar feature of destructive thyroid autoimmunity," <i>Autoimmunity</i> <u>4</u> : 267-276 (1989)
FB	Demeure <i>et al.</i> , "Human naive CD4 T cells produce interleukin-4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions," <i>European Journal of Immunology</i> <u>25</u> : 2722-2725 (1995)
FC	Derwent #008306271 WPI Acc. No. 1990-193272/199025 (citing, WO Patent Publication WO90/05541, the parent of Japanese Patent Publication No. JP 2883201, published April 19, 1999).
FD	Dillman <i>et al.</i> , "Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma," <i>Cancer</i> <u>68</u> : 1-8 (1991)
FE	Dillman <i>et al.</i> , "Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A national biotherapy study group trial," <i>J. Clin. Oncology</i> <u>9</u> (7): 1233-1240 (1991)
FF	Ding, L. <i>et al.</i> , "Activation of CD4 ⁺ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation)," <i>European J. of Immunology</i> <u>24</u> : 859-866 (1994).
FG	Eastcott <i>et al.</i> , "Adoptive transfer of cloned T helper cells ameliorates periodontal disease in nude rats," <i>Oral Microbiol. Immunol.</i> <u>9</u> : 284-289 (1994)
FH	Economou <i>et al.</i> , "In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes," <i>Journal of Clinical Investigation</i> <u>97</u> : 515-521 (1996)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FI	Elsässer-Beile <i>et al.</i> , "Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3 ⁺ , CD4 ⁺ , and CD8 ⁺ renal-cell-carcinoma-infiltrating lymphocytes," <i>Cancer Immunology, Immunotherapy</i> <u>48</u> : 204-208 (1999)
FJ	Elsässer-Beile <i>et al.</i> , "Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas," <i>Tumour Biology</i> <u>19</u> : 470-476 (1998)
FK	Elson <i>et al.</i> , "T cell subpopulation phenotypes in filarial infections: CD27 negativity defines a population greatly enriched for T _H 2 cells," <i>Internat. Immunol.</i> <u>6</u> : 1003-1009 (1993)
FL	Emori <i>et al.</i> , "Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4," <i>Biotherapy</i> <u>9</u> : 249-255 (1996)
FM	Englemann <i>et al.</i> , "Activation of human T lymphocyte subsets: Helper and suppressor/cytotoxic T cells recognize and respond to distinct histocompatibility antigens," <i>J. Immunol.</i> <u>127</u> : 2124-2129 (1981)
FN	Fan <i>et al.</i> , "Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection," <i>Mediators of Inflammation</i> <u>7</u> : 295-297 (1994)
FO	Faradji <i>et al.</i> , "Large scale isolation of human blood monocytes by continuous flow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients," <i>J. Immunol. Meth.</i> <u>174</u> : 297-309 (1994)
FP	Figlin <i>et al.</i> , "Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor," <i>Journal of Urology</i> <u>158</u> : 740-745 (1997)
FQ	Finke <i>et al.</i> , "Characterization of a human renal cell carcinoma specific cytotoxic CD8 ⁺ T cell line," <i>Journal of Immunotherapy</i> <u>11</u> : 1-11 (1992)
FR	Finke <i>et al.</i> , "Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon- γ secretion, and proliferation," <i>Journal of Immunotherapy with Emphasis on Tumor Immunology</i> <u>15</u> : 91-104 (1994)
FS	Fiorentino <i>et al.</i> , "Two types of mouse T helper cell," <i>J. Exp. Med.</i> <u>170</u> : 2081-2095 (1989)
FT	Firestein <i>et al.</i> , "A new murine CD4 ⁺ T cell subset with an unrestricted cytokine profile," <i>J. Immunol.</i> <u>143</u> : 518-525 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FU	Foon <i>et al.</i> , "Renal cell carcinoma treated with continuous-infusion interleukin-2 with <i>ex vivo</i> -activated killer cells," <i>J. Immunotherapy</i> <u>11</u> : 184-190 (1992)
FV	Fortis <i>et al.</i> , "Increased interleukin-10 serum levels in patients with solid tumours," <i>Cancer Letters</i> <u>104</u> : 1-5 (1996)
FW	Foulis <i>et al.</i> , "Insulinitis in type 1 (insulin-dependent) diabetes mellitus in Man-macrophages, lymphocytes, and interferon- μ containing cells," <i>J. Pathol.</i> <u>165</u> : 97-103 (1991)
FX	Fowell <i>et al.</i> , "Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 ⁺ T cell subset that inhibits this autoimmune potential," <i>J. Exp. Med.</i> <u>177</u> : 627-636 (1993)
FY	Fowler <i>et al.</i> , "Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice," <i>Advances in Bone Marrow Purging and Processing: Fourth International Symposium</i> 533-540 (1994)
FZ	Fowler <i>et al.</i> , "Donor CD4-Enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice," <i>Blood</i> <u>84</u> (10): 3540-3549 (1994)
GA	Freedman <i>et al.</i> , "Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial," <i>J. Immunol.</i> <u>16</u> : 198-210 (1994)
GB	Friess <i>et al.</i> , "Treatment of advanced pancreatic cancer with Mistletoe: results of a pilot trial," <i>Anticancer Research</i> <u>16</u> : 915-920 (1996)
GC	Fujimoto <i>et al.</i> , "Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state," <i>Journal of Immunology</i> <u>158</u> : 5619-5626 (1997)
GD	Fujisao and Tsuda, "Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma," <i>British Journal of Haematology</i> <u>103</u> : 308-310 (1998)
GE	Funauchi <i>et al.</i> , "Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus," <i>Scandinavian Journal of Rheumatology</i> <u>27</u> : 219-224 (1998)
GF	Gabrilovich <i>et al.</i> , "Dendritic cells in antitumor immune responses," <i>Cellular Immunology</i> <u>170</u> : 111-119 (1996)
GG	Galandrini <i>et al.</i> , "Antibodies to CD44 trigger effector functions of human T cell clones," <i>J. Immunol.</i> <u>150</u> : 4225-4235 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


GH	Garlie <i>et al.</i> , "T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer," <i>Journal of Immunotherapy</i> <u>22</u> : 336-345 (1999)
GI	Gaudernack <i>et al.</i> , "Isolation of pure functionally active CD8 ⁺ T cells positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres," <i>J. Immun. Meth.</i> <u>90</u> : 179-187 (1986)
GJ	Ghosh <i>et al.</i> , "Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth," <i>Journal of the National Cancer Institute</i> <u>87</u> (19): 1478-1483 (1995)
GK	Goedegbuure <i>et al.</i> , "Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study," <i>J. Clin. Oncol.</i> <u>13</u> : 1939-1949 (1995)
GL	Goedegebuure <i>et al.</i> , "Simultaneous production of T Helper-1-like Cytokines and Cytolytic activity by tumor-specific T cells in ovarian and breast cancer," <i>Cellular Immunology</i> <u>175</u> : 150-156 (1997)
GM	Gold <i>et al.</i> , "Autolymphocyte therapy," <i>J. Surgical Res.</i> <u>59</u> : 270-286 (1995)
GN	Gold <i>et al.</i> , "Adoptive Tumor immunotherapy using human CD4 ⁺ T-cells," <i>Br. J. Cancer</i> <u>67</u> : 865 (1993)
GO	Gorelik <i>et al.</i> , "Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor," <i>Immunology, Immunotherapy</i> <u>39</u> : 117-126 (1994)
GP	Grabbe <i>et al.</i> , "Dendritic cells as initiators of tumor immune responses: A Possible strategy for tumor immunotherapy," <i>Immunology Today</i> <u>16</u> : 117-121 (1995)
GQ	Graham <i>et al.</i> , "Influenza virus-specific CD4 ⁺ T Helper Type 2 T lymphocytes do not promote recovery from experimental virus infection," <i>Journal of Experimental Medicine</i> <u>180</u> : 1273-1282 (1994)
GR	Graham <i>et al.</i> , "The use of <i>ex vivo</i> -activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study," <i>Seminars in Urology</i> <u>11</u> : 27-34 (1993)
GS	Grau <i>et al.</i> , "Implications of cytokines in immunopathology: Experimental and clinical data," <i>Eur. Cytokine Net.</i> <u>1</u> : 203-210 (1990)
GT	Grimm <i>et al.</i> , "Lymphokine-activated killer cell phenomenon," <i>J. Exp. Med.</i> <u>155</u> : 1823-1841 (1982)
GU	Gullino <i>et al.</i> , "Tissue culture on artificial capillaries," <i>Meth. Enzymol.</i> <u>58</u> : 178-184 (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

RECEIVED
SEP 06 2002
TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GV	Hager <i>et al.</i> , "Tumor-associated antigens produced by mouse mammary tumor cells in artificial capillary culture," <i>J. Natl. Cancer Inst.</i> <u>69</u> : 1359-1365 (1982)
GW	Hammel <i>et al.</i> , "Effect of interleukin-1 α on the <i>in vitro</i> activation of tumor-draining lymph node cells for adoptive immunotherapy," <i>J. Immunotherapy</i> <u>16</u> : 1-12 (1993)
GX	Han <i>et al.</i> , "A new type of CD4 ⁺ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice," <i>Journal of Autoimmunity</i> <u>9</u> : 331-339 (1996)
GY	Handgretinger <i>et al.</i> , "Rapid method for purification of CD56 ⁺ natural killer cells with preferential enrichment of the CD56 ^{bright} subset," <i>Journal of Clinical Laboratory Analysis</i> <u>8</u> : 443-446 (1994)
GZ	Hansel <i>et al.</i> , "Purification of human blood eosinophils by negative selection using immunomagnetic beads," <i>Journal of Immunological Methods</i> <u>122</u> : 97-103 (1989)
HA	Hansen <i>et al.</i> , "Monoclonal antibodies identifying a novel T-cell antigen and Ia antigen of human lymphocytes," <i>Immunogenetics</i> <u>10</u> : 247-260 (1980)
HB	Hara <i>et al.</i> , "Human T cell activation," <i>J. Exp. Med.</i> <u>161</u> : 1513-1524 (1985)
HC	Hara <i>et al.</i> , "Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2," <i>Japanese Journal of Cancer Research</i> <u>87</u> : 724-729 (1996)
HD	Hauer <i>et al.</i> , "Analysis of Th1 and Th2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated <i>in vitro</i> with <i>Helicobacter pylori</i> ," <i>Journal of Clinical Pathology</i> <u>50</u> : 957-959 (1997)
HE	Hawke <i>et al.</i> , "Stimulation of human T cells by sparse antigen captured on immunomagnetic particles," <i>J. of Immunol. Methods</i> <u>155</u> : 41-48 (1992).
HF	Heniford <i>et al.</i> , "Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2," <i>Journal of Surgical Research</i> <u>56</u> : 82-88 (1994)
HG	Henschler <i>et al.</i> , "Maintenance of transplantation potential in <i>ex vivo</i> expanded CD34 ⁺ - selected human peripheral blood progenitor cells," <i>Blood</i> <u>84</u> : 2898-2903 (1994)
HH	Herberman <i>et al.</i> , "Adoptive therapy with purified CD8 cells in HIV infection," <i>AIDS/Cancer Therapies</i> , 35-44.
HI	Hirshberg <i>et al.</i> , "Chronic eosinophilic pneumonia associated with cutaneous T-cell lymphoma," <i>American Journal of Hematology</i> <u>60</u> : 143-147 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


HJ	Ho <i>et al.</i> , "A phase 1 study of adoptive transfer of autologous CD8 ⁺ lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS," <i>Blood</i> <u>81</u> : 2093-2101 (1993)
HK	Horiguchi <i>et al.</i> , "Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells," <i>Cancer Research</i> <u>59</u> : 2950-2956 (1999)
HL	Hrouda <i>et al.</i> , "Immunotherapy of advanced prostate cancer: a phase I/II trial using <i>Mycobacterium vaccae</i> (SRL172)," <i>British Journal of Urology</i> <u>82</u> : 568-573 (1992)
HM	Hsieh <i>et al.</i> , "Differential regulation of T helper phenotype development by interleukins 4 and 10 in an $\alpha\beta$ T-cell-receptor transgenic system," <i>Proc. Natl. Acad. Sci. USA</i> <u>89</u> : 6065-6089 (1992).
HN	Huang <i>et al.</i> , "Non-small cell lung cancer-derived soluble mediators and prostaglandin E ₂ enhance peripheral blood lymphocyte IL-10 transcription and protein production," <i>Journal of Immunology</i> <u>157</u> : 5512-5520 (1996)
HO	Huet <i>et al.</i> , "T cell activation via CD2 [T, gp50]: The role of accessory cells in activating resting T cells via CD2," <i>J. Immunol.</i> <u>137</u> : 1420-1428 (1986)
HP	Huettner <i>et al.</i> , "Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas," <i>American Journal of Pathology</i> <u>146</u> : 317-322 (1995)
HQ	Igletseme <i>et al.</i> , "Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, TH ₁ Lymphocyte clone," <i>Regional Immunology</i> <u>5</u> : 317-324 (1993)
HR	Inagawa <i>et al.</i> , "Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions," <i>Anticancer Research</i> <u>18</u> : 3957-3964 (1998)
HS	Ito <i>et al.</i> , "Lung Carcinoma: Analysis of T Helper Type 1 and 2 cells and T Cytotoxic Type 1 and 2 cells by intracellular cytokine detection with flow cytometry," <i>Cancer</i> <u>85</u> : 2359-2367 (1999)
HT	Jacobs <i>et al.</i> , "Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix," <i>Clinical and Experimental Immunology</i> <u>111</u> : 219-224 (1998)
HU	Jacobs <i>et al.</i> , "Efficient immunoselection of cytolytic effectors with a magnetic cell sorter," <i>Research in Immunology</i> <u>144</u> : 141-150 (1993)
HV	Jensen <i>et al.</i> , "Production of anchorage-dependent cells-problems and their possible solutions," <i>Biotechnol. Bioeng.</i> <u>23</u> : 2703-2716 (1981)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HW	Jiang <i>et al.</i> , "Increased Intraplatelet and urinary transforming growth factor- β in patients with multiple myeloma," <i>Acta Haematologica</i> <u>12</u> : 1-6 (1995)
HX	June <i>et al.</i> , "T-Cell Proliferation Involving the CD28 Pathway Is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", <i>Molecular and Cell Biology</i> , <u>7</u> (12): 4472-4481 (1987).
HY	Karawajew <i>et al.</i> , "A simple and sensitive method to study effects mediated by soluble lymphokines as demonstrated by the interaction of CD4 + and CD8 + cell subsets during T cell activation," <i>The Journal of Immunological Methods</i> <u>173</u> : 27-31 (1994).
HZ	Kim <i>et al.</i> , "IL-10 Production in cutaneous basal and squamous cell carcinomas," <i>Journal of Immunology</i> <u>155</u> : 2240-2247 (1995)
IA	Kitahara <i>et al.</i> , "Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432," <i>Journal of Laryngology and Otology</i> <u>110</u> : 449-453 (1996)
IB	Klimas <i>et al.</i> , "Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion," <i>AIDS</i> <u>8</u> : 1073-1081 (1994)
IC	Knazek <i>et al.</i> , "Brief communication: Formation of solid human mammary carcinoma <i>in vitro</i> ," <i>J. Natl. Cancer Inst.</i> <u>58</u> : 419-422 (1977)
ID	Knazek <i>et al.</i> , "Hormone production by cells grown <i>in vitro</i> on artificial capillaries," <i>Exp. Cell Res.</i> <u>84</u> : 251-254 (1974)
IE	Knazek <i>et al.</i> , "Cell culture on artificial capillaries: An approach to tissue growth <i>in vitro</i> ," <i>Science</i> <u>173</u> : 65-67 (1972)
IF	Knoefel <i>et al.</i> , "A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 Melanoma," <i>Journal of Interferon and Cytokine Research</i> <u>17</u> : 95-102 (1997)
IG	Kobayashi <i>et al.</i> , "A Pathogenic Role of Th2 Cells and Their Cytokine Products on the Pulmonary Metastasis of Murine B16 Melanoma," <i>Journal of Immunology</i> <u>160</u> : 5869-5873 (1998)
IH	Kobayashi <i>et al.</i> , "Inhibition of pulmonary metastasis by Z-100, an immunomodulatory lipid-arabinomannan extracted from <i>Mycobacterium Tuberculosis</i> , in mice inoculated with B16 melanoma," <i>Anti-Cancer Drugs</i> <u>8</u> : 156-163 (1997)
II	Koretz <i>et al.</i> , "Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer," <i>Arch. Surg.</i> <u>126</u> : 898-903 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


IJ	Krüger-Krasagakes <i>et al.</i> , "Expression of interleukin 10 in human melanoma," <i>Journal of Cancer</i> <u>70</u> : 1182-1185 (1994)
IK	Kuiper <i>et al.</i> , "Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation," <i>European J. of Immunology</i> <u>24</u> (9): 1956-60 (1994).
IL	Lane <i>et al.</i> , "Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation," <i>Blood</i> <u>85</u> : 275-282 (1995)
IM	Lea <i>et al.</i> , "Characterization of human mononuclear cells after positive selection with immunomagnetic particles," <i>Scand. J. Immunol.</i> <u>23</u> : 509-519 (1986)
IN	Lea <i>et al.</i> , "Magnetic Monosized polymer particles for fast and specific fractionation of human mononuclear cells," <i>Scan. J. Immunol.</i> <u>22</u> : 207-216 (1985)
IO	Ledbetter <i>et al.</i> , "Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells," <i>J. Immunol.</i> <u>135</u> : 2331-2336 (1985)
IP	Ledbetter <i>et al.</i> , "Signal transduction through CD4 receptors: Stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor," <i>Eur. J. Immunol.</i> <u>18</u> : 525-532 (1988)
IQ	Ledbetter <i>et al.</i> , "Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression," <i>J. Immunol.</i> <u>135</u> : 1819-1825 (1985)
IR	Ledbetter <i>et al.</i> , "Antibody Binding to CD5 (Tp67) and Tp44 Cell Surface Molecules: Effects on Cyclic Nucleotides, Cytoplasmic Free Calcium, and cAMP-Mediated Suppression," <i>The Journal of Immunology</i> <u>137</u> (10): 3299-3305 (1986).
IS	Lee <i>et al.</i> , "T Helper 2-Dominant Antilymphoma Immune Response Is Associated With Fatal Outcome," <i>Blood</i> <u>90</u> : 1611-1617 (1997)
IT	Leite-De-Moraes <i>et al.</i> , "IL-4-producing NK T Cells are biased towards IFN- γ production by IL-12. Influence of the microenvironment on the functional capacities of NK T Cells," <i>European Journal of Immunology</i> <u>28</u> : 1507-1515 (1998)
IU	Levine <i>et al.</i> , "Ex Vivo Replicative Potential of Adult Human Peripheral Blood CD4+ T Cells," <i>Transplantation Proceedings</i> <u>29</u> : 2028 (1997)
IV	Li <i>et al.</i> , "Cyclophosphamide Given After Active Specific Immunization Augments Antitumor Immunity by modulation of TH1 Commitment of CD4+ T Cells," <i>Journal of Surgical Oncology</i> <u>67</u> : 221-227 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IW	Liblau <i>et al.</i> , "Th1 and Th2 CD4 ⁺ T Cells in the pathogenesis of organ-specific autoimmune diseases," <i>Immunology Today</i> <u>16</u> : 34-38 (1995)
IX	Lindqvist <i>et al.</i> , "Enhanced IL-4-mediated D10.G4.1 Proliferation with suboptimal concentrations of anti-IL-4 receptor Monoclonal antibodies," <i>J. Immunol.</i> <u>150</u> : 394-398 (1993)
IY	Lowes <i>et al.</i> , "T Helper Cytoine mRNA Is Increased in Spontaneously Regressing Primary Melanomas," <i>Journal of Investigative Dermatology</i> <u>108</u> : 914-919 (1997)
IZ	Lúdvíksson <i>et al.</i> , "The effect of TGF-61 on immune responses of naïve versus memory CD4 ⁺ Th1/Th2 T cells," <i>European Journal of Immunology</i> <u>30</u> : 2101-2111 (2000)
JA	Lum <i>et al.</i> , "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients," <i>Bone Marrow Transplantation</i> <u>12</u> : 565-571 (1993).
JB	Lum <i>et al.</i> , "In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen," <i>Cell. Immunol.</i> <u>72</u> : 122-129 (1982)
JC	Luyten <i>et al.</i> , "Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation," <i>J. Biol. Chem.</i> <u>264</u> (23): 13377-13380 (1989)
JD	Lynch <i>et al.</i> , "Interleukin 7 promotes long-term <i>in vitro</i> growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy <i>in vivo</i> ," <i>J. Exp. Med.</i> <u>179</u> : 31-42 (1994)
JE	Manetti <i>et al.</i> , "CD30 expression by CD8 ⁺ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8 ⁺ CD30 ⁺ T cell clones in human immunodeficiency virus infection," <i>J. Exp. Med.</i> <u>180</u> : 2407-2411 (1994)
JF	Manger <i>et al.</i> , "T cell activation: Differences in the signals required for IL 2 Production by nonactivated and activated T cells," <i>J. Immunol.</i> <u>135</u> : 3669-3673 (1985)
JG	Mantovani <i>et al.</i> , "Nuova Técnica di Purificazione Linfocitaria Per La Tipizzazione HLA," (1989) <i>Bollettino - Societa Italiana Biologia Sperimentale</i> <u>65</u> (10): 967-973 (1989)
JH	Marcus <i>et al.</i> , "The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced <i>in vivo</i> antitumor activity," <i>J. Immunotherapy</i> <u>15</u> : 105-112 (1994)
JI	Martin <i>et al.</i> , "A 44 Kilodalton Cell Surface Homodimer Regulates Interleukin 2 Production By Activated Human T Lymphocytes", <i>J. of Immunol.</i> <u>136</u> (9): 3282-3287 (1986).
JJ	Mastsumura <i>et al.</i> , "Characteristics and <i>in vivo</i> homing of long-term T-cell Lines and clones derived from tumor-draining lymph nodes," <i>Cancer Res.</i> <u>54</u> : 2744-2750 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JK	Ménétrier-Caux <i>et al.</i> , "Renal cell carcinoma induces interleukin 10 and prostaglandin E ₂ production by monocytes," <i>British Journal of Cancer</i> <u>79</u> : 119-132 (1999)
JL	Miller <i>et al.</i> , "Large scale <i>ex vivo</i> expansion and activation of human natural killer cells for autologous therapy," <i>Bone Marrow Transplantation</i> <u>14</u> : 555-562 (1994)
JM	Mosmann <i>et al.</i> , "The expanding universe of T-cell subset: Th1, Th2 and more," <i>Immunology Today</i> <u>17</u> (3): 138-146 (1996)
JN	Mosmann <i>et al.</i> , "Two types of murine helper T cell clone," <i>Journal of Immunology</i> <u>136</u> : 2348-2357 (1986)
JO	Mosmann, T.R. and R.L. Coffman, "TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties," <i>Ann. Rev. Immunology</i> <u>7</u> : 145-173 (1989)
JP	Mosmann, T.R. and R.L. Coffman, "Heterogeneity of Cytokine Secretion Patterns and Functions of Helper T Cells," <i>Advances in Immunology</i> <u>46</u> : 111-147 (1989)
JQ	Mulder <i>et al.</i> , "Culture of tumor-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumor cells does not affect tumor-specificity," <i>Cancer Immunol. Immunother.</i> <u>41</u> : 293-301 (1995)
JR	Nabel <i>et al.</i> , "An inducible transcription factor activates expression of human immunodeficiency virus in T cells," <i>Nature</i> <u>326</u> : 711-3 (1987).
JS	Nabioullin <i>et al.</i> , "Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages," <i>Journal of Leukocyte Biology</i> <u>55</u> : 437-442 (1994)
JT	Nagler <i>et al.</i> , "Red blood cell depletion and enrichment of CD34 ⁺ Hematopoietic progenitor cells from human umbilical cord blood using soybean agglutinin and CD34 immunoselection," <i>Exp. Hematol.</i> <u>22</u> : 1134-1140 (1994)
JU	Nakagomi <i>et al.</i> , "Lack of Interleukin-2 (IL-2) Expression and Selective Expression of IL-10 mRNA in Human Renal Cell Carcinoma," <i>International Journal of Cancer</i> <u>63</u> : 366-371 (1995)
JV	Nakajima <i>et al.</i> , "Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression," <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 7889-7893 (1994)
JW	Nicholson <i>et al.</i> , "An Altered Peptide Ligand Mediates Immune Deviation and Prevents Autoimmune Encephalomyelitis," <i>Immunity</i> <u>3</u> : 397-405 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JX	Niessner <i>et al.</i> , "Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR)," <i>Clin. Exp. Immunol.</i> <u>101</u> : 428-435 (1995)
JY	Nijhuis <i>et al.</i> "Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies," <i>Cancer Immunol. Immunotherapy</i> <u>32</u> : 245-50 (1990).
JZ	Nishimura <i>et al.</i> , "The critical role of Th 1-dominant immunity in tumor immunology," <i>Cancer Chemotherapy and Pharmacology</i> <u>46</u> (Suppl): S52-S61 (2000)
KA	Nishimura <i>et al.</i> , "Generation, Propagation, and Targeting of Human CD4 + Helper.Killer T Cells induced by Anti-CD3 Monoclonal Antibody Plus Recombinant IL-2," <i>J. Immunol.</i> <u>148</u> : 285-291 (1992)
KB	Nitta <i>et al.</i> , "Selective expression of interleukin-10 gene within glioblastoma multiforme," <i>Brain Research</i> <u>649</u> : 122-128 (1994)
KC	Noben-Trauth <i>et al.</i> , "Conventional, Naive CD4 + T Cells Provide an Initial Source of IL-4 During Th2 Differentiation," <i>Journal of Immunology</i> <u>165</u> : 3620-3625 (2000)
KD	O'Garra <i>et al.</i> , "Role of cytokines in determining T-lymphocyte function," <i>Immunology</i> <u>6</u> : 458-466 (1994)
KE	Oelke <i>et al.</i> , "Generation and Purification of CD8 + Melan-A-specific Cytotoxic T Lymphocytes for Adoptive Transfer in Tumor Immunotherapy," <i>Clinical Cancer Research</i> <u>6</u> : 1997-2005 (2000)
KF	Ohno <i>et al.</i> , Lectin-activated Killer cells rapidly induced by pokeweed mitogen conjugated beads and their <i>in vivo</i> antitumor effects, <i>Int. J. Immunopharmacol.</i> <u>16</u> : 761-768 (1994)
KG	Oka <i>et al.</i> , "An immunomodulatory arabinomannan extracted from <i>Mycobacterium tuberculosis</i> , Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice," <i>Immunology Letters</i> <u>70</u> : 109-117 (1999)
KH	Okamoto <i>et al.</i> , "The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells," <i>Cancer Immunol. Immunother</i> <u>40</u> : 173-181 (1995)
KI	Okamoto <i>et al.</i> , "Local Injection of OK432 Can Augment the Th1-Type T-Cell Response in Tumor-Draining Lymph Node Cells and Increase Their Immunotherapeutical Potential," <i>International Journal of Cancer</i> <u>70</u> : 598-605 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


KJ	Okarma <i>et al.</i> , "The AIS collector: A new technology for stem cell purification," <i>Advances in Bone Marrow Purging and Processing: proceedings of the Third International Symposium on Bone Marrow Purging and Processing held in San Diego, CA, October 1991</i> Worthington-White <i>et al.</i> (Eds.) New York: Wiley-Liss, Inc. pp.487-504 (1992)
KK	Okutomi <i>et al.</i> , "Clinical Effects of Adjuvant Therapy Using Z-100 (Ancer 20 Injection) for Oral Cancer - Prevention of Stomatitis and Hematopoietic Impairment," <i>Gan To Kagaku Ryoho (Japanese Journal of Cancer and Chemotherapy)</i> <u>27(1)</u> : 65-71 (2000)
KL	Onishi <i>et al.</i> , "An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma," <i>Bju International</i> <u>83</u> : 488-492 (1999)
KM	Oxholm <i>et al.</i> , "Cytokine expression in labial salivary glands from patients with primary Sjogrens syndrome," <i>Autoimmunity</i> <u>12</u> : 185-191 (1992)
KN	Pai <i>et al.</i> "Cross-linking CD28 leads to activation of 70-kDa S6 kinase," <i>European Journal of Immunology</i> <u>24(10)</u> : 2364-2368 (1994).
KO	Palliard <i>et al.</i> , "Simultaneous production of IL-2, IL-4, and IFN- γ by activated human CD4 ⁺ and CD8 ⁺ T cell clones," <i>J. Immunol.</i> <u>141</u> : 849-855 (1988)
KP	Partington <i>et al.</i> , "A novel method of cell separation based on dual parameter immunomagnetic cell selection," <i>Journal of Immunological Methods</i> <u>223</u> : 195-205 (1999)
KQ	Pellegrini <i>et al.</i> , "Disregulation in TH1 and TH2 subsets of CD4 ⁺ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression," <i>Cancer Immunology Immunotherapy</i> <u>42</u> : 1-8 (1996)
KR	Pierrès <i>et al.</i> , "Triggering CD 28 molecules synergize with CD 2 (T 11.1 and T 11.2)-mediated T cell activation," <i>Eur. J. Immunol.</i> <u>18</u> : 685-690 (1988)
KS	Polanski <i>et al.</i> , "Differentiation of Th2 cells from precursors in RA peripheral blood," <i>Arthritis & Rheumatism</i> <u>39(9 Suppl.)</u> : pS126 (1996)
KT	Poorafshar <i>et al.</i> , "MMCP-8, the first lineage-specific differentiation marker for mouse basophils. Elevated numbers of potent IL-4-producing and MMCP-8-positive cells in spleens of malaria-infected mice," <i>European Journal of Immunology</i> <u>30</u> : 2660-2668 (2000)
KU	Powrie <i>et al.</i> , "Regulatory interactions between CD45RB ^{High} and CD45RB ^{Low} CD4 ⁺ T cells are important for the balance between protective and pathogenic cell-mediated immunity," <i>J. Exp. Med.</i> <u>179</u> : 589-600 (1994)
KV	Powrie <i>et al.</i> , "Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity <i>in vivo</i> ," <i>European Journal of Immunology</i> <u>23</u> : 3043-3049 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/1500

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KW	Poynter <i>et al.</i> , "Activation of NK1.1 ⁺ T Cells <i>in Vitro</i> and Their Possible Role in Age-Associated Changes in Inducible IL-4 Production," <i>Cellular Immunology</i> <u>179</u> : 22-29 (1997)
KX	Prasad <i>et al.</i> , "Nutritional and Zinc Status of Head and Neck Cancer Patients: An Interpretive Review," <i>Journal of the American College of Nutrition</i> <u>17</u> : 409-418 (1998)
KY	Prince <i>et al.</i> , "Preparation of CD8 ^{bright} and CD8 ^{dim} lymphocyte populations using two positive selection methods in tandem," <i>Journal of Immunological Methods</i> <u>165</u> : 139-148 (1993)
KZ	Puchetti <i>et al.</i> , "A T _H 1-T _H 2-like switch in candidiasis: New perspectives for therapy," <i>Trends Microbiol.</i> <u>3</u> (6): 237-240 (1995)
LA	Punnonen <i>et al.</i> , "Cytokine Production Profiles in the Peritoneal Fluids of Patients with Malignant or Benign Gynecologic Tumors," <i>Cancer</i> <u>83</u> : 788-96 (1998)
LB	Quayle <i>et al.</i> , "Theumatoid inflammatory T-cell clones express mostly Th-1 but also Th2 and mixed (Th0-like) cytokine patterns," <i>Scand. J. Immunol.</i> <u>38</u> : 75-82 (1993)
LC	Reinherz <i>et al.</i> , "Separation of functional subsets of human T cells by a monoclonal antibody," <i>Proc. Natl. Acad. Sci. USA</i> <u>76</u> : 4061-4065 (1979)
LD	Renzo <i>et al.</i> , "Extracorporeal photochemistry restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma," <i>Immunology</i> <u>92</u> : 99-103 (1997)
LE	Riddell <i>et al.</i> , "Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones," <i>Science</i> <u>257</u> : 238-241 (1992)
LF	Riddell <i>et al.</i> , "CD8 ⁺ cytotoxic T cell therapy of cytomegalovirus and HIV infection," <i>Current Opinion in Immunology</i> <u>5</u> : 484-491 (1993)
LG	Riddell <i>et al.</i> , "Principles for adoptive T cell therapy of human viral diseases," <i>Ann. Rev. Immunology</i> <u>13</u> : 545-586 (1995)
LH	Robinson <i>et al.</i> , "Predominant T _H 2-Like Bronchoalveolar T-Lymphocyte Population in atopic Asthma," <i>New England Journal of Medicine</i> <u>326</u> : 298-304 (1992)
LI	Romagnani <i>et al.</i> , "Regulation of the development of type 2 T-helper cells in allergy," <i>Current Opinion in Immunology</i> <u>6</u> : 838-846 (1994)
LJ	Romagnani <i>et al.</i> , "HIV can induce a T _H 1 to T _H 0 shift, and preferentially replicates in CD4 ⁺ T-cell clones producing T _H 2-type cytokines," <i>60th Forum in Immunology</i> , pp. 611-617 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LK	Romagnani, S., "Human T _H 1 and T _H 2" subsets: doubt no more", <i>Immunol. Today</i> , <u>12</u> :256-257 (1991)
LL	Romani <i>et al.</i> , "Proliferating dendritic cell progenitors in human blood", <i>J. Exp. Med.</i> , <u>180</u> :83-93 (1994)
LM	Romani <i>et al.</i> , "Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance", <i>Infection and Immunity</i> , <u>59</u> :4647-4654 (1991)
LN	Rosen <i>et al.</i> , "Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells - a possible role for breast cancer-associated p43," <i>Cancer Letters</i> <u>127</u> : 129-134 (1998)
LO	Rosenberg <i>et al.</i> , "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma," <i>N. Engl. J. Med.</i> <u>319</u> : 1676-1680 (1988)
LP	Rosenberg <i>et al.</i> , "Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer," <i>N. Engl. J. Med.</i> <u>313</u> : 1485-1492 (1985)
LQ	Rosenberg <i>et al.</i> , "A progress on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone," <i>N. Engl. J. Med.</i> <u>316</u> : 889-897 (1987)
LR	Roussel <i>et al.</i> , "Predominance of a type 2 intratumoural response in fresh tumour-infiltrating lymphocytes from human gliomas," <i>Clinical and Experimental Immunology</i> <u>105</u> : 344-352 (1996)
LS	Rutzky <i>et al.</i> , "Human colon adenocarcinoma cells. III. <i>In vitro</i> organoid expression and carcinoembryonic antigen kinetics in hollow fiber culture," <i>J. Natl. Cancer Inst.</i> <u>63</u> (4): 893-902 (1979)
LT	Sacchi <i>et al.</i> , "Induction of tumor regression in experimental model of human head and neck cancer by human A-Lak cells and IL-2," <i>Int. J. Cancer</i> , <u>47</u> : 784-791 (1991)
LU	Saed <i>et al.</i> , "Mycosis Fungoides Exhibits a TH1-Type Cell-Mediated Cytokine Profile Whereas Sezary Syndrome Expresses a Th2-Type Profile," <i>Journal of Investigative Dermatology</i> <u>103</u> : 29-33 (1994)
LV	Salgaller <i>et al.</i> , "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated <i>in vitro</i> with synthetic peptides," <i>Cancer Res.</i> <u>55</u> : 4972-4979 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 05 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

LW	Saoudi <i>et al.</i> , "TH2 activated cells prevent experiential autoimmune unweoretinitis, a TH1-dependent autoimmune disease," <i>Eur. J. Immunol.</i> <u>23</u> : 3096-3103 (1993)
LX	Sasama <i>et al.</i> , "Effect of IL-4, IFN- γ and IL-12 on Cytokine Production from Human CD45RA and CD45RO CD4 T Cell Precursors," <i>International Archives of Allergy and Immunology</i> <u>117</u> : 255-262 (1998)
LY	Sato <i>et al.</i> , "Impaired Production of TH1 Cytokines and Increased Frequency of Th2 Subsets in PBMC from Advanced Cancer Patients," <i>Anticancer Research</i> <u>18</u> : 3951-3956 (1998)
LZ	Saxton <i>et al.</i> , "Adoptive Transfer of Anti-CD3-Activated CD4+ T Cells Plus Cyclophosphamide and Liposome-Encapsulated Interleukin-2 Cure Murine MC-38 and 3LL Tumors and Establish Tumor-Specific Immunity," <i>Blood</i> <u>89</u> : 2529-2536 (1997)
MA	Schoof <i>et al.</i> , "CD4+ T Cell Clones Isolated from Human Renal Cell Carcinoma Possess the Functional Characteristics of the Th2 Helper Cells," <i>Cellular Immunology</i> <u>150</u> : 114-123 (1993)
MB	Scott <i>et al.</i> , "The role of T-cell subsets and cytokines in the regulation of infection," <i>Immunology Today</i> , <u>12</u> : 346-348, (1991).
MC	Scott <i>et al.</i> , "Role of Cytokines and CD4+ T-Cell Subsets in the Regulation of Parasite Immunity and Disease", <i>Immunol. Rev.</i> , <u>112</u> : 161-182 (1989)
MD	Scouten <i>et al.</i> "Reversible Immobilization of Antibodies on Magnetic Beads," <i>Analytical Biochem.</i> <u>205</u> : 313-318 (1992).
ME	Seder <i>et al.</i> , "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon μ production and diminishes interleukin 4 inhibition of such priming," <i>Proc. Natl. Acad. Sci. USA</i> <u>90</u> : 10188-10192 (1993)
MF	Sedlmayr <i>et al.</i> , "Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells," <i>J. Immunotherapy</i> <u>10</u> : 336-346 (1991)
MG	Serrano <i>et al.</i> , "The Patterns of IL2, IFN- γ , IL4 and IL5 Gene Expression in Hodgkin's Disease and Reactive Lymph Nodes Are Similar," <i>Haematologica</i> <u>82</u> : 542-549 (1997)
MH	Shanafelt <i>et al.</i> , "Costimulatory signals can selectively modulate cytokine production by subsets of CD4+ T cells," <i>J. Immunol.</i> <u>154</u> : 1684-1690 (1995).
MI	Sher <i>et al.</i> , "Role of T-Cell Derived Cytokines in the Downregulation of Immune Responses in Parasitic and Retroviral Infection", <i>Immunol. Rev.</i> <u>127</u> : 183-204 (1992)

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

FORM PTO-1449 (Modified)

AUG 29 2002


 OIPE
PATENT & TRADEMARK OFFICE
ATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016
 LIST OF PATENTS AND PUBLICATIONS FOR
 APPLICANT'S INFORMATION DISCLOSURE
 STATEMENT
APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MJ	Shimizu <i>et al.</i> , "Costimulation of proliferative responses of resting CD4 ⁺ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin," <i>J. Immunol.</i> <u>145</u> : 59-67 (1990)
MK	Shinomiya <i>et al.</i> , "Anti-Metastatic Activity Induced by the <i>In Vivo</i> Activation of Purified Protein Derivative (PPD)- Recognizing Th1 Type CD4 + T Cells," <i>Immunobiology</i> <u>193</u> : 439-455 (1995)
ML	Shurin <i>et al.</i> , "Th1/TH2 balance in cancer, transplantation and pregnancy," <i>Springer Seminars in Immunopathology</i> <u>21</u> : 339-359 (1999)
MM	Simon <i>et al.</i> , "Divergent T-cell cytokine patterns in inflammatory arthritis," <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 8562-8566 (1994)
MN	Singh <i>et al.</i> , "Cutting Edge: Activation of NK T Cells by CD1 and α -Galactosylceramide Directs Conventional T Cells to the Acquisition of a Th2 Phenotype," <i>Journal of Immunology</i> <u>163</u> : 2373-2377 (1999)
MO	Smith <i>et al.</i> , "Production of interleukin-10 by Human Bronchogenic Carcinoma," <i>American Journal of Pathology</i> <u>145</u> (1): 18-25 (1994)
MP	Spertini <i>et al.</i> , "Signals delivered via MHC class II molecules synergize with signals delivered via TCR/CD3 to cause proliferation and cytokine gene expression in T cells," <i>J. Immunol.</i> <u>149</u> : 65-70 (1992)
MQ	Springer <i>et al.</i> , "Adhesion receptors of the immune system," <i>Nature</i> <u>346</u> : 425-434 (1990)
MR	Sredni <i>et al.</i> , "Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS101," <i>Journal of the National Cancer Institute</i> <u>88</u> (18): 1276-84 (1996)
MS	Sredni <i>et al.</i> , "The Protective Role of the Immunomodulator AS101 Against Chemotherapy-Induced Alopecia Studies on Human and Animal Models," <i>International Journal of Cancer</i> <u>65</u> : 97-103 (1996)
MT	Sredni <i>et al.</i> , "Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated With Carboplatin and Etoposide," <i>Journal of Clinical Oncology</i> <u>13</u> (9): 2342-2353 (1995)
MU	Stanciu <i>et al.</i> , "Production of IL-8 and IL-4 by positively and negatively selected CD4 + and CD8 + human T cells following a four step cell separation method including magnetic cell sorting (MACS)," <i>Journal of Immunological Methods</i> <u>187</u> : 107-115 (1996)
MV	Sugie <i>et al.</i> , "Stimulation of NK-like YT cells via leukocyte function-associated antigen (LFA)-1," <i>J. Immunol.</i> <u>154</u> : 1691-1698 (1995)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
24731-504B

SERIAL NO.
10/071,016

APPLICANT
GRUENBERG, Michael L.

FILING DATE
February 7, 2002

GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


MW	Swabb <i>et al.</i> , "Diffusion and convection in normal and neoplastic tissues," <i>Cancer Res.</i> <u>34</u> : 2814-2822 (1974)
MX	Sznol, M and W.J. Urba, "Adoptive immunotherapy," Chapter 13 in <i>Cancer Chemotherapy and Biological Responses Modifiers</i> , Pinedo, H.M. <i>et al.</i> (Eds.) Amsterdam, New York: Elsevier <u>14</u> : 227-248 (1993)
MY	Tabata <i>et al.</i> , "Th2 Subset Dominance among Peripheral Blood T Lymphocytes in Patients with Digestive Cancers," <i>American Journal of Surgery</i> <u>177</u> : 203-208 (1999)
MZ	Takahashi <i>et al.</i> , "Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion," <i>Jpn. J. Cancer Res.</i> <u>86</u> : 861-866 (1995)
NA	Takeuchi <i>et al.</i> , "Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma," <i>Cancer Immunol Immunother</i> <u>43</u> : 375-381 (1997)
NB	Tamura <i>et al.</i> , "T cell activation through TCR/-CD3 complex IL-2 production of T cell clones stimulated with anti-CD3 without cross-linkage," <i>J. Immunol.</i> <u>48</u> : 2370-2377 (1992)
NC	Tanaka <i>et al.</i> , "Flow Cytometric Analysis of Helper T Cell Subsets (Th1 and Th2) in Healthy Adults," <i>Rinsho Byori Japanese Journal of Clinical Pathology</i> <u>46</u> : 1247-1251 (1998)
ND	Tax <i>et al.</i> , "Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells," <i>Nature</i> <u>304</u> : 445-447 (1983)
NE	Tendler <i>et al.</i> , "Abnormal Cytokine Expression in Sezary And Adult T-Cell Leukemia Cells Correlates with the Functional Diversity between These T-Cell Malignancies," <i>Cancer Research</i> <u>54</u> : 4430-4435 (1994)
NF	Thanhäuser <i>et al.</i> , "The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells," <i>Cancer Immunology, Immunotherapy</i> <u>40</u> : 103-108 (1995)
NG	Thompson <i>et al.</i> , "Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma," <i>J. Clin. Oncol.</i> <u>10</u> : 960-968 (1992)
NH	Thygesen <i>et al.</i> , "Immunity to experimental <i>Salmonella typhimurium</i> infections in rats," <i>APMIS</i> <u>102</u> : 489-494 (1994)
NI	To <i>et al.</i> , "Therapeutic Efficacy of Th1 and TH2 L-selectin-CD4 + Tumor-Reactive T Cells," <i>Laryngoscope</i> <u>110</u> : 1648-1654 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


NJ	Torpey III <i>et al.</i> , "Effects of adoptive immunotherapy with autologous CD8 + T Lymphocytes on Immunologic Parameters: Lymphocyte Subsets and Cytotoxic Activity," <i>Clinical Immunol. Immunopathol.</i> <u>68</u> : 263-272 (1993)
NK	Toso, J.F. <i>et al.</i> , "MAGE-1-Specific Precursor Cytotoxic T-Lymphocytes Present among Tumor-Infiltrating Lymphocytes from a Patient with Breast Cancer: Characterization and Antigen-Specific Activation", <i>Cancer Res.</i> , <u>56</u> : 16-20 (1996)
NL	Turner <i>et al.</i> , "Human T cells from autoimmune and normal individuals can produce tumor necrosis factor," <i>Eur. J. Immunol.</i> <u>17</u> : 1807-1814 (1987)
NM	Tze <i>et al.</i> , "Long-term survival of adult rat islets of Langerhans in artificial capillary culture units," <i>Diabetes</i> , <u>26</u> : 185-191 (1977)
NN	Urban <i>et al.</i> , "The importance of Th2 cytokines in protective immunity to nematodes," <i>Immunological Reviews</i> , <u>127</u> : 205-220 (1992)
NO	Urdahl <i>et al.</i> "Accessory Cell-derived Costimulatory Signals Regulate T Cell Proliferation," <i>Ann. N.Y. Acad. Sci.</i> <u>636</u> : 33-42 (1991).
NQ	Utsugi <i>et al.</i> , "Prevention of recurrent diabetes in syngeneic islet-transplanted NOD Mice by transfusion of autoreactive T lymphocytes," <i>Transplantation</i> <u>57</u> : 1799-1804 (1994)
NR	Van Lier <i>et al.</i> , "Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen," <i>J. Immunol.</i> <u>139</u> : 1589-1596 (1987)
NS	Van Lunzen <i>et al.</i> , "Investigations on autologous T-cells for adoptive immunotherapy of AIDS," Chapter 6 in <i>Cell Activation and Apoptosis in HIV Infection</i> , Andrieu, J.M and Lu, W. (Eds.) New York: Plenum Press, pp. 57-70 (1995)
NT	Van Wauwe <i>et al.</i> "OKT3: A Monoclonal Anti-Human T Lymphocyte Antibody With Potent Mitogenic Properties," <i>The Journal of Immunology</i> <u>124</u> (6): 2708-2713 (1980)
NU	Vandenberghe <i>et al.</i> , "Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: Evidence for signal transduction through CD5," <i>Eur. J. Immunol.</i> <u>21</u> : 251-259 (1991)
NV	Von Flidner <i>et al.</i> "Production of Tumor Necrosis Factor- α by Naive Or Memory T Lymphocytes Activated via CD28," <i>Cellular Immunology</i> <u>139</u> : 198-207 (1992).
NW	Vowels <i>et al.</i> , "Th2 Cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma," <i>Journal of Investigative Dermatology</i> <u>103</u> : 669-673 (1994)
NX	Wang <i>et al.</i> , "Early IL-4 Production Driving Th2 Differentiation in a Human in Vivo Allergic Model is Mast Cell Derived," <i>Clinical Immunology</i> <u>90</u> : 47-54 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Th1 CELL ADOPTIVE IMMUNOTHERAPY**



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 06 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


NY	Wang <i>et al.</i> , "Selective Cytokine Gene Expression in Renal Cell Carcinoma Tumor Cells and Tumor-Infiltrating Lymphocytes," <i>International Journal of Cancer</i> <u>61</u> : 780-785 (1995)
NZ	Weber <i>et al.</i> , "Activation Through CD3 Molecule Leads to Clonal Expansion of All Human Peripheral Blood T Lymphocytes: Functional Analysis of Clonally Expanded Cells, The <i>Journal of Immunology</i> <u>135</u> (4): 2337-2342 (1985).
OA	Weber <i>et al.</i> , "Effects of a Standardized Mistletoe Preparation on Metastatic B16 Melanoma Colonization in Murine Lungs", <i>Arzneimittel-Forschung</i> , <u>48</u> :497-502 (1998)
OB	Werz <i>et al.</i> , "Purification of transforming growth factor beta1 from human platelets", <i>Pharmazie</i> , <u>51</u> :893-896 (1996)
OC	Whiteside <i>et al.</i> , "Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus", <i>Blood</i> , <u>81</u> :2085-2092 (1993)
OD	Wolf <i>et al.</i> , "Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries", <i>Trans Amer Soc Artif Int Organs</i> , <u>21</u> :16-27 (1975)
OE	Wong <i>et al.</i> , "TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+ T Cell Response", <i>J Immunol</i> , <u>162</u> :2251-2258 (1999)
OF	Yamamura <i>et al.</i> , "Local Expression of Antiinflammatory Cytokines in Cancer", <i>Journal of Clinical Investigation</i> , <u>91</u> :1005-1010 (1993)
OG	Yamamura <i>et al.</i> , Erratum: In reference to: "Defining Protective Responses to Pathogens: Cytokine Profiles in Leprosy Lesions" by Yamamura <i>et al.</i> (11 Oct., p. 277; corrected sequence), <i>Science</i> , <u>255</u> :12 (1992)
OH	Yamamura <i>et al.</i> , "Defining Protective Responses to Pathogens: Cytokine Profiles in Leprosy Lesions", <i>Science</i> , <u>254</u> :277-279 (1991)
OI	Yang <i>et al.</i> , "In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation", <i>J Immunol</i> , <u>155</u> :3897-3903 (1995)
OJ	Yang <i>et al.</i> , "Default development of cloned human naive CD4 T cells into interleukin-4- and interleukin-5- producing effector cells", <i>Eur J Immunol</i> , <u>25</u> :3517-3520 (1995)
OK	Yannelli <i>et al.</i> , "The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer", <i>J Immunol Meth</i> , <u>139</u> :1-16 (1991)
OL	Yoon <i>et al.</i> , "Prophylactic effect of Korean mistletoe (<i>Viscum album coloratum</i>) extract on tumor metastasis is mediated by enhancement of NK cell activity", <i>International Journal of Immunopharmacology</i> , <u>20</u> :163-172 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY



FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
24731-504BSERIAL NO.
10/071,016APPLICANT
GRUENBERG, Michael L.FILING DATE
February 7, 2002GROUP
1636

TECH CENTER 1600/2900

SEP 10 6 2002

RECEIVED

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OM	Zhang <i>et al.</i> , "T-cell cytokine responses in human infection with <i>Mycobacterium tuberculosis</i> ", <i>Infect Immun</i> , <u>63(8)</u> : 3231-3234 (1995)
ON	Zitvogel <i>et al.</i> , "Therapy of Murine Tumors with Tumor Peptide-pulsed Dendritic Cells: Dependence on T Cells, B7 Costimulation, and T Helper Cell 1-associated Cytokines", <i>J Exp. Med.</i> , <u>183</u> :87-97 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY